Keywords: UK, NICE, GlaxoSmithKline, Hycamtin, Eli Lilly, Efient, Daiichi Sankyo

UK’s NICE backs GSK’s Hycamtin for cervical cancer and Lilly’s Efient for preventing blood clots

Article | 28 October 2009

Print This

The UK’s National Institute for Health and Clinical Excellence (NICE), which recommends treatments to be made available under the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in